Literature DB >> 22104004

Serum proteomics in patients with diagnosis of abdominal aortic aneurysm.

Cristiano Spadaccio1, Fabio Di Domenico, Marzia Perluigi, Mario Lusini, Alessandra Giorgi, Maria Eugenia Schininà, Carla Blarzino, Elvio Covino, Massimo Chello, Raffaella Coccia.   

Abstract

BACKGROUND: Molecular mechanisms underlying abdominal aneurysm (AAA) formation and rupture are not well understood. Early detection and repair of AAA may reduce the high mortality rates associated with rupture. Serum proteomics allows the detection of alterations in the expression of proteins, guiding further studies on these target molecules as potential markers. Analysis of proteomic profile of asymptomatic patients with AAA allows the identification of reliable predictors or markers of disease presence or progression.
METHODS: A proteomics approach based on two-dimensional electrophoresis and mass spectrometry was used to compare serum proteomic profiles of patients with AAA who are candidates for surgical repair compared with healthy controls. We analyzed in parallel the proteomic profile of subjects with cardiac heart failure to discriminate these two pathologies, which show similar pattern of systemic inflammation process.
RESULTS: We identified in AAA subjects four serum proteins that show altered expression profile and that could be specifically linked to AAA pathology. We discuss the role of our identified proteins with their possible implications in disease outcome.
CONCLUSIONS: This approach could provide an initial screening tool that may drive the basis for further research in the field of cardiovascular diseases. These results need to be validated in larger studies to find potential markers of AAA presence or progression to use in clinical settings.
SUMMARY: A proteomics approach was used to compare serum proteomic profiles of patients with abdominal aortic aneurysm who are candidates for surgical repair compared with healthy controls. Four serum proteins showed altered expression profile that could be correlated with the pathology. This approach could provide an initial screening tool that may drive the basis for further research in the field of cardiovascular diseases.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22104004     DOI: 10.1016/j.carpath.2011.09.008

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  6 in total

Review 1.  Proteomic approaches to identify circulating biomarkers in patients with abdominal aortic aneurysm.

Authors:  Dan Bylund; Anders E Henriksson
Journal:  Am J Cardiovasc Dis       Date:  2015-09-15

Review 2.  Proteomic analysis in cardiovascular research.

Authors:  Teiji Oda; Ken-ichi Matsumoto
Journal:  Surg Today       Date:  2015-04-19       Impact factor: 2.549

3.  CURRENT DEVELOPMENTS IN DRUG ELUTING DEVICES: Introductory Editorial: Drug-Eluting Stents or Drug-Eluting Grafts? Insights from Proteomic Analysis.

Authors:  Cristiano Spadaccio; Francesco Nappi; Nawwar Al-Attar; Raffaella Coccia; Marzia Perluigi; Fabio Di Domenico
Journal:  Drug Target Insights       Date:  2017-01-03

4.  Proteomic analysis of the abdominal aortic aneurysm wall.

Authors:  Jiri Molacek; Jan Mares; Vladislav Treska; Karel Houdek; Jan Baxa
Journal:  Surg Today       Date:  2013-03-22       Impact factor: 2.549

5.  Quantitative HDL Proteomics Identifies Peroxiredoxin-6 as a Biomarker of Human Abdominal Aortic Aneurysm.

Authors:  Elena Burillo; Inmaculada Jorge; Diego Martínez-López; Emilio Camafeita; Luis Miguel Blanco-Colio; Marco Trevisan-Herraz; Iakes Ezkurdia; Jesús Egido; Jean-Baptiste Michel; Olivier Meilhac; Jesús Vázquez; Jose Luis Martin-Ventura
Journal:  Sci Rep       Date:  2016-12-09       Impact factor: 4.379

6.  Identification of Potential Plasma Biomarkers for Abdominal Aortic Aneurysm Using Tandem Mass Tag Quantitative Proteomics.

Authors:  Anders E Henriksson; Markus Lindqvist; Carina Sihlbom; Jörgen Bergström; Dan Bylund
Journal:  Proteomes       Date:  2018-10-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.